Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION
REGISTRATION OF DEBT FINANCING INSTRUMENTS BY THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS AND REGISTRATION OF CORPORATE BONDS BY THE CHINA SECURITIES REGULATORY COMMISSION

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of China Resources Pharmaceutical Group Limited (the "**Company**") is pleased to announce that China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) ("**CR Pharmaceutical Commercial**"), a non-wholly-owned subsidiary of the Company, has received a notice of acceptance of registration (Zhong Shi Xie Zhu [2026] No. PDFI177) (the "**Debt Financing Instruments Registration Notice**") issued by the National Association of Financial Market Institutional Investors in relation to the proposed issuance of debt financing instruments by CR Pharmaceutical Commercial in the People's Republic of China (the "**PRC**"). The Debt Financing Instruments Registration Notice shall be effective for a period of two years from the issue date of the Debt Financing Instruments Registration Notice, during which CR Pharmaceutical Commercial may issue debt financing instruments, including ultra-short-term debenture, short-term debenture, medium term notes and perpetual notes, in an aggregate amount of RMB10 billion in tranches.

The Board further announces that CR Pharmaceutical Commercial has received a notice of registration approval (Zheng Jian Xu Ke [2026] No. 3164) (the "**Corporate Bonds Registration Notice**") issued by the China Securities Regulatory Commission in relation to the proposed issuance of corporate bonds by CR Pharmaceutical Commercial to qualified investors in the PRC. The Corporate Bonds Registration Notice shall be effective for a period of 24 months from the issue date of the Corporate Bonds Registration Notice, during which CR Pharmaceutical Commercial may issue corporate bonds in an aggregate amount of RMB10 billion in tranches.

The Company will make further announcements in relation to the proposed issuance of debt financing instruments and corporate bonds as and when appropriate.

As the proposed issuance of the debt financing instruments and corporate bonds may or may not proceed, shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 16 November 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.